Rhythm Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$2.45 | -$2.27 | -$2.36 |
| Q2 2024 | 4 | -$0.74 | -$0.68 | -$0.71 |
| Q3 2024 | 3 | -$0.84 | -$0.77 | -$0.80 |
| Q4 2024 | 9 | -$1.04 | -$0.42 | -$0.75 |
| Q1 2025 | 6 | -$0.83 | -$0.68 | -$0.77 |
| Q2 2025 | 5 | -$0.77 | -$0.71 | -$0.74 |
| Q3 2025 | 5 | -$0.75 | -$0.69 | -$0.72 |
| Q4 2025 | 5 | -$0.70 | -$0.65 | -$0.67 |
Rhythm Pharmaceuticals, Inc. Earnings Date And Information
Rhythm Pharmaceuticals, Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-0.73 earnings per share for the quarter, topping analysts' consensus estimates of $-0.8 by $0.07. The company had revenue of 33.25 M for the quarter and had revenue of 77.43 M for the year. Rhythm Pharmaceuticals, Inc. has generated $-3 earnings per share over the last year ($-3.2 diluted earnings per share) and currently has a price-to-earnings ratio of -14.1. Rhythm Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Rhythm Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.73 | $32.52 M | $33.25 M | ||
| 08/14/2024 | Q2 2024 | -$0.53 | $28.79 M | $29.08 M | ||
| 05/07/2024 | Q1 2024 | -$2.34 | -$2.35 | -0.01 | $25.97 M | |
| 02/29/2024 | Q4 2023 | -$0.70 | $24.23 M | |||
| 11/08/2023 | Q3 2023 | -$0.76 | $22.18 M | $22.50 M | ||
| 08/01/2023 | Q2 2023 | -$0.80 | -$0.82 | -0.02 | $15.03 M | $19.22 M |
| 05/02/2023 | Q1 2023 | -$0.71 | -$0.91 | -0.2 | $11.47 M | |
| 03/01/2023 | Q4 2022 | -$0.82 | -$0.76 | 0.06 | $8.79 M | |
| 11/08/2022 | Q3 2022 | -$1.01 | -$0.83 | 0.18 | $4.76 M | $4.28 M |
| 08/03/2022 | Q2 2022 | -$0.89 | $2.57 M | $9.07 M | ||
| 05/03/2022 | Q1 2022 | -$0.98 | -$1.05 | -0.07 | $1.50 M | |
| 03/01/2022 | Q4 2021 | -$1.00 | -$0.85 | 0.15 | $1.82 M | |
| 11/02/2021 | Q3 2021 | -$0.84 | -$0.70 | 0.14 | $934,200 | $1.03 M |
| 08/03/2021 | Q2 2021 | -$0.75 | -$0.70 | 0.05 | $551,000 | $274,000 |
| 05/03/2021 | Q1 2021 | -$0.23 | $0.92 | 1.15 | $35,000 | |
| 03/01/2021 | Q4 2020 | -$0.81 | -$0.79 | 0.02 | $0 | |
| 11/02/2020 | Q3 2020 | -$0.83 | -$0.77 | 0.06 | $500,000 | $0 |
| 08/03/2020 | Q2 2020 | -$0.83 | -$0.71 | 0.12 | $0 | |
| 05/04/2020 | Q1 2020 | -$0.80 | -$0.78 | 0.02 | $0 | |
| 03/02/2020 | Q4 2019 | -$0.91 | -$0.78 | 0.13 | $0 |
Rhythm Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Rhythm Pharmaceuticals, Inc.'s earnings date?
Rhythm Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
-
Did Rhythm Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Rhythm Pharmaceuticals, Inc. (:RYTM) reported $-0.73 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.8 by $0.07.
-
How can I listen to Rhythm Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Rhythm Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Rhythm Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Rhythm Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Rhythm Pharmaceuticals, Inc. generate each year?
Rhythm Pharmaceuticals, Inc. (:RYTM) has a recorded annual revenue of $77.43 M.
-
How much profit does Rhythm Pharmaceuticals, Inc. generate each year?
Rhythm Pharmaceuticals, Inc. (:RYTM) has a recorded net income of $77.43 M. Rhythm Pharmaceuticals, Inc. has generated $-3.2 earnings per share over the last four quarters.
-
What is Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio?
Rhythm Pharmaceuticals, Inc. (:RYTM) has a price-to-earnings ratio of -14.1 and price/earnings-to-growth ratio is -20.4.
